0000105770-16-000053.txt : 20160112 0000105770-16-000053.hdr.sgml : 20160112 20160112090103 ACCESSION NUMBER: 0000105770-16-000053 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20160112 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160112 DATE AS OF CHANGE: 20160112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WEST PHARMACEUTICAL SERVICES INC CENTRAL INDEX KEY: 0000105770 STANDARD INDUSTRIAL CLASSIFICATION: FABRICATED RUBBER PRODUCTS, NEC [3060] IRS NUMBER: 231210010 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-08036 FILM NUMBER: 161337722 BUSINESS ADDRESS: STREET 1: 101 GORDON DR STREET 2: P O BOX 645 CITY: LIONVILLE STATE: PA ZIP: 19341-0645 BUSINESS PHONE: 6105942900 MAIL ADDRESS: STREET 1: 101 GORDON DRIVE STREET 2: PO BOX 645 CITY: LIONVILLE STATE: PA ZIP: 19341-0645 FORMER COMPANY: FORMER CONFORMED NAME: WEST CO INC DATE OF NAME CHANGE: 19990405 8-K 1 form8kjan122016.htm 8-K 8-K


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported) – January 12, 2016
 
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)

 
 
 
 
 
Pennsylvania
 
1-8036
 
23-1210010
(State or other jurisdiction
of Incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
 
 
 
 
530 Herman O. West Drive, Exton, PA
 
 
 
19341-0645
(Address of principal executive offices)
 
 
 
(Zip Code)

 Registrant’s telephone number, including area code: 610-594-2900

Not Applicable
(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 





Item 7.01 Regulation FD Disclosure.

On January 12, 2016, West Pharmaceutical Services, Inc. (the "Company") announced a change to its organization and reporting structure that will support the Company in its next phase of growth and development. Beginning in 2016, the Company will no longer operate two separate units for its Packaging and Delivery Systems businesses. The Company is establishing global Commercial, Operations and Innovation & Technology organizations in order to provide more comprehensive and tailored offerings to its customers across the Company’s rich portfolio of products and services.

Separately, the Company also announced the appointment of Quintin Lai, Ph.D., to Vice President, Corporate Development, Strategy and Investor Relations ("IR"). Dr. Lai will oversee corporate strategy and investor relations for the Company and report directly to Mr. Green.

Prior to joining the Company, Dr. Lai served as Vice President of Investor Relations and Corporate Strategy at Sigma-Aldrich Corporation, where he was responsible for developing a global strategy for that S&P 500 company, as well as creating an industry-leading IR function. From 2002-2012, Dr. Lai served as Managing Director and Senior Equity Research analyst of the Life Science Tools and Diagnostic sector at Robert W. Baird & Company. Dr. Lai also spent eight years as a Senior Research Engineer at Atlantic Richfield (ARCO).

Dr. Lai received a Ph.D. in Chemical Engineering from the University of Wisconsin-Madison, an MBA from the University of Chicago Booth School of Business and a B.S. in Chemical Engineering from the University of Alabama. He is also a CFA charterholder.

A copy of the press release issued by the Company is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)
Exhibits
 
 
99.1
West Pharmaceutical Services, Inc. Press Release, dated January 12, 2016.






SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
WEST PHARMACEUTICAL SERVICES, INC.
 
 
 
 
 
/s/ William J. Federici
 
William J. Federici
 
Senior Vice President and Chief Financial Officer
 
 
 
 
January 12, 2016
 






EXHIBIT INDEX

Exhibit No.
Description
99.1
West Pharmaceutical Services, Inc. Press Release, dated January 12, 2016.




 EX-99.1 2 exh991pressreleasejan122016.htm EXHIBIT 99.1 Exhibit


Exhibit 99.1

Media Inquiries:
Emily Denney
Communications
(610) 594-3035
emily.denney@westpharma.com
Investors:
Michael A. Anderson
Vice President and Treasurer
(610) 594-3345
michael.anderson@westpharma.com

John Woolford
Westwicke Partners
(443) 213-0506
 
West Announces New Organizational Structure

Exton, PA - Jan. 12, 2016 - West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced a change to its organization and reporting structure that will support the Company in its next phase of growth and development. Beginning in 2016, the company will no longer operate two separate units for its Packaging and Delivery System businesses. West is establishing global Commercial, Operations and Innovation & Technology organizations in order to provide more comprehensive and tailored offerings to its customers across the Company’s rich portfolio of products and services.

“This is an exciting time for West, as we continue to expand our global footprint, grow our integrated drug containment and delivery product offerings, and take steps to optimize our manufacturing network to help our biotech and pharmaceutical customers deliver innovative, new medicines to patients across the globe,” said Eric M. Green, President and Chief Executive Officer. “I am confident that this new organizational structure and the team we have in place to lead it will drive our strategy forward and deliver results for West, our customers and our shareholders.”

The new global Commercial Team at West will drive growth across three markets: Biologics, Generics and Pharma, and will include marketing, sales and contract manufacturing services, as well as technical customer support for West’s full portfolio of offerings. Karen Flynn, Senior Vice President and Chief Commercial Officer, who previously held the position of President, Pharmaceutical Packaging Systems, will lead this organization.

A new global Innovation & Technology Team has been established to create the next generation of products from incubation to the commercial stage, across the packaging, containment and delivery product areas. John Paproski, Senior Vice President and Chief Technology Officer, who previously served as President, Pharmaceutical Delivery Systems, will lead this team.

As announced in October, the Company is accelerating efforts throughout its global supply chain to drive operational excellence to improve service, quality and profitability. The global Operations Team will report directly to Mr. Green.

The remainder of West’s executive leadership team is unchanged:

•
William Federici, Senior Vice President and Chief Financial Officer

•
Annette Favorite, Senior Vice President and Chief Human Resources Officer




•
George Miller, Senior Vice President, General Counsel and Corporate Secretary

More details on the organization and reporting structure will be provided at the Company’s Investor Day, planned for March 10, 2016, in New York, NY.

Separately, the Company also announced today the appointment of Quintin Lai, Ph.D., to Vice President, Corporate Development, Strategy and Investor Relations (IR). Dr. Lai will oversee corporate strategy and investor relations for West and report directly to Mr. Green.

Prior to joining West, Dr. Lai served as Vice President of Investor Relations and Corporate Strategy at Sigma-Aldrich Corporation, where he was responsible for developing a global strategy for that S&P 500 company, as well as creating an industry-leading IR function. From 2002-2012, Dr. Lai served as Managing Director and Senior Equity Research analyst of the Life Science Tools and Diagnostic sector at Robert W. Baird & Company. Dr. Lai also spent eight years as a Senior Research Engineer at Atlantic Richfield (ARCO).

Dr. Lai received a Ph.D. in Chemical Engineering from the University of Wisconsin-Madison, an MBA from the University of Chicago Booth School of Business and a B.S. in Chemical Engineering from the University of Alabama. He is also a CFA charterholder.

About West

West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world’s pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West’s 2014 sales of $1.42 billion reflect the daily use of approximately 110 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as "plans," "create," "grow," "continue to expand," "will drive," or "deliver results" or similar words or phrases, which are predictions of or indicate future events or trends and which do not relate solely to historical matters. While forward-looking statements reflect West's good faith beliefs, assumptions and expectations, they are not guarantees of future performance and there can be no assurance that the reorganization described in this release will accomplish the intended results. Furthermore, except as required by law, West disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions, new information or other changes. Known material risks, uncertainties and other factors that can affect future results are discussed or incorporated by reference in periodic reports under the Securities Exchange Act of 1934, as amended, filed by West from time to time with the Securities and Exchange Commission.

# # #


 GRAPHIC 3 exh991logo01122016.jpg begin 644 exh991logo01122016.jpg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end GRAPHIC 4 westlogo01122016.jpg begin 644 westlogo01122016.jpg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